| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.096 | 0.05 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.05 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.06 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.089 | 0.06 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |